ꀅ EN

Beyond mutations.

Towards functional precision.


Unlocking therapeutic targets with patient-derived organoids and high-throughput functional genomics.

ꂃ ꁹ

About TRiCBiO

Cancer is far more than a collection of genetic mutations. Genomics and sequencing have long guided our search for answers, yet these approaches capture merely a fragment of the broader picture. What truly matters is whether a target gene is functionally active in the patient and contributes to tumor progression.

 

We harness cutting-edge functional genomics tools and industry-leading organoid technology to systematically identify and validate key driver genes within human-derived models that closely mimic the tumor’s native microenvironment. This allows us to go beyond differential expression or mutation analysis, pinpointing functional targets that influence therapeutic response and disease progression with precision.

 

TRiCBiO is dedicated to making cancer treatment more precise and effective. By directly measuring gene function, we are redefining the paradigm of target discovery and validation - offering actionable treatment options for current patients and providing a robust foundation for the next generation of targeted therapies.

Core Team

ꁲ

Bachelor of Peking University,
PhD, Ohio State University, USA

> 15 years of target discovery expert, pre-clinical research and development experience of new oncology drugs

More than 10 years in the United States Novartis, Fuente and other international first-class pharmaceutical companies as the chief researcher.

For the first time in the industry, the concept of in vivo target screening has been proposed, and the world's first method for high-throughput screening of targets in situ in tumors has been developed.

Novartis Pharmaceuticals-Pharmaceutical Innovation Award, Wexler Medical Center Publication Achievement Award, International Cachexia Association Young Fellow Award (the only winner in basic research)

Dr. Wei He

ꁲ

PhD, Ohio State University, USA


>15 years of experience in clinical statistics, pharmacology of oncology drugs, and clinical trials.

Involved as Principal Officer in clinical trial design and FDA approval of a variety of marketed drugs including Ceritinib(ZYKADIA®),Ribociclib(KISQALI®), Alpelisib (PIQRAY®), and Tisagenlecleucel (KYMRIAH®)

He was a senior scientist in the clinical pharmacology department of Novartis and a senior manager of the clinical transformation department of Dapeng Pharmaceutical (Taiho Oncology).

Novartis Pharmaceuticals-Outstanding Contribution Award

Dr. Yin Han

ꁲ

Ph.D., Alaba University, USA, Postdoctoral Fellow, Stanford University School of Medicine, USA

> 15 years of experience in organoid research, the world's top cancer organoid experts

Research Scientist, Stanford University School of Medicine, USA

Organoid 2.0: Inventor of Integrated Gas-Liquid Culture (ALI)

industry, the ALI method is used to prepare tumor organoids, recreating the patient's tumor immune microenvironment for accurate evaluation of the efficacy of immunotherapy and other innovative drugs.

academic achievements were published in Cell, Nature Medicine and other top journals, with the highest impact factor of a single document being 53.440 points and the highest number of citations being 742 times.

Dr. Xingnan Li

TRiCBiO brings together scientists and industry experts from top scientific research institutions such as Stanford University, Peking University, Tsinghua University and Fudan University, as well as international pharmaceutical companies such as Novartis and Pfizer. It has both cutting-edge academic innovation and original research. Practical experience in drug development. The team has long been engaged in key technical areas such as tumor target discovery, drug mechanism research, organoid modeling and functional genomics, focusing on early innovation in new drug development "from 0 to 1", focusing on new target mining, functional verification and preclinical mechanism research. Relying on the industry-leading target discovery platform, database system and industrial transformation capabilities, TRICBIO is accelerating the discovery and landing of new targets and new mechanism drugs, and continues to empower partners to achieve real differentiation breakthroughs.